ONE OF BIOHK2022'S MANY TOPICS BIOETHICS, LAW AND INVESTMENT 香港国际生物科技展的多个话题之一 生物伦理,法律和投资 IDEAL PLACE 理想地方 As the world’s second largest biotech IPO hub, Hong Kong is the ideal place to have the necessary conversations regarding Bioethics, Law and Investments. China’s demand for Biotechnology have grown at an exponential rate in the past decade, experiencing significant surges in both production and demand. 作为世界第二大生物科技IPO枢纽,香港是就生物伦理,法律和投资等范畴进行必要对话的理想地方。 在过去的十年中,中国对生物科技的需求以指数级的速度增长,产量和需求均出现大幅增长。 IMPORTANT 重要 With an ageing population and the recent COVID-19 outbreak, it is not a surprise the biotech and healthcare field sector are transforming significantly, it’s overall income growth and profound involvement of social capital even during such challenging times proves the importance and necessity of the biotech sector. Investments in the biotech and healthcare field are continuously driven by innovation, and as the world becomes more digitalised, along with the COVID-19 crisis we have witnessed the digital transformation of the healthcare industry. This opens a wide door of opportunities for investments with huge potential in generating new capital investment boom in the biotech and healthcare sector. 随着人口老龄化和近期2019新型冠状病毒病爆发,生物科技和医疗保健领域发生的重大变革并不令人感到意外,即使在如此艰难的时期,它的总体收入增长和社会资本的深入参与也证明了生物科技的重要性和必要性。 创新不断推动着对生物科技和医疗保健领域的投资,随着世界变得更加数字化,再加上2019新型冠状病毒病危机,我们见证了医疗保健行业的数字化转型。 这为具有巨大潜力的投资机会打开了大门,在生物科技和医疗保健领域产生了巨大的新资本投资热潮。 INVALUABLE 无价 At BIOHK2022, be a part of the discussions between government officials, key investors and industry leaders to discuss on going changes in policies and regulations in the field, corporate governance, the importance of robust intellectual property, investment opportunities in China, listing and IPOs in Hong Kong and China. Our One2One Partnering session will bring together global investors, entrepreneurs and market stakeholders, do not miss out on the chance to widen your international network and make successful partnerships. 在香港国际生物科技展上,参加政府官员,主要投资者和行业领袖之间的讨论,讨论该领域政策和法规的不断变化,公司治理,强大的知识产权的重要性,在中国的投资机会,在香港及中国上市和IPO。 我们的一对一商机洽谈将汇聚全球投资者,企业家和市场利益相关者,不要错过扩大您的国际网络并建立成功合作伙伴关系的机会。 CALLING FOR NEW CONFERENCE TOPICS AND SPEAKERS 呼吁新学术演讲题目及嘉宾 ! We are always on the lookout for new conference topics and speakers! If there is a topic that you would like us to feature, or someone you know who would make an excellent addition to our event, feel free to let us know. 我们一直寻找新的学术演讲题目及嘉宾!如果您认识某个精彩的题目或您身边认识一位出色的演讲嘉宾,请随时联络我们以作提名。 TOPICS 题目 POLICIES AND REGULATIONS 政策和法规 01 POLICIES & REGULATIONS FOR CLINICAL TRIALS IN GREATER CHINA 大中华地区临床试验的政策和法规 02 CONCERNS IN REGULATING GLOBAL R&D ON INNOVATIVE DRUGS 监管全球创新药物研发的担忧 03 SIMPLIFYING REGULATION & POLICIES TO PROMOTE INTERNATIONAL COLLABORATION 简化法规和政策以促进国际合作 Welcoming international talent and world renowned scientific teams and labs 欢迎国际人才和世界知名的科学团队和实验室 04 HOW INNOVATION IS DRIVING THE DEVELOPMENT OF POLICIES, TALENT RECRUITMENT AND CLINICAL TRIAL STANDARDS IN THE BIOTECH INDUSTRY 创新如何推动生物科技行业的政策,人才招聘和临床试验标准的发展 National perspective, Investigating case studies and initiatives 国家观点,调查案例研究和举措 05 POLICIES TO DEVELOP THE INDUSTRIAL AND INNOVATION ECOSYSTEMS REQUIRED IN A SUSTAINABLE BIO ECONOMY 发展可持续的生物经济所需的工业和创新生态系统的政策 06 ACCEPTING AND REGULATING CONTROVERSIAL INNOVATION 接受和规范有争议的创新 07 THE DISTRIBUTION OF HUMAN RESOURCES IN THE GBA: DIRECTION AND PERSPECTIVE 大湾区中的人力资源分布:方向和前景 CORPORATE GOVERNANCE 公司治理 01 WHAT HONG KONG HAS TO OFFER 香港有什么能提供 Immense research capabilities, unique status as One Country, Two Systems, Innovation and Technology is at the top of the Government’s Policy Agenda, robust and trustworthy city with conducive Intellectual Property, 2nd Largest fundraising centre for biotech companies 庞大的研究能力,一国两制的独特地位,创新与科技是政府政策议程的重中之重,拥有有利知识产权的强大而可信赖的城市,第二大生物科技集資中心 02 HOW HONG KONG CAN PROVE ITSELF AS A BIOTECHNOLOGY HUB 香港如何证明自己是一个生物科技中心 FINANCE 金融 01 ACCESSING CAPITAL FOR DEVELOPMENT: STRATEGIES FOR EQUITY FINANCING 筹集发展资金:股权融资战略 02 ACHIEVE GOOD REGULATORY PLANNING FOR ECONOMICALLY EFFICIENT CLINICAL DEVELOPMENT FOR YOUR COMPANY 为您的公司实现经济有效而良好的临床开发监管计划 03 BUSINESS VALUATION OF BIOTECH COMPANIES 生物科技公司的业务价值 04 ACHIEVING COST EFFICIENT INNOVATION 实现经济有效的创新 05 ACCESSING THE CHINA MARKET: LICENSING RIGHTS TO CLINICAL STAGE ASSETS IN CHINA 进入中国市场:在中国临床阶段资产的许可权 06 THE IMPORTANCE OF SUSTAINABLE COMPETITIVENESS BETWEEN BIOTECH COMPANIES WORLDWIDE / GBA 全球生物科技公司/大湾区之间可持续竞争力的重要性 07 BUILDING A SCIENCE AND TECHNOLOGY FINANCIAL SYSTEM FOR THE GBA BIOTECH COMMUNITY UNDER IMPLEMENTATION OF GBA POLICIES 实施大湾区政策为大湾区生物科技社区建立科技金融体系 INTELLECTUAL PROPERTY 知识产权 01 THE IMPORTANCE FOR STRATEGIZING EFFECTIVE AND EFFICIENT IP DUE DILIGENCE PROCESSES 制定有效和效率高的知识产权尽职调查流程的重要性 02 REMAINING PROFITABLE: PROTECTING YOUR INTELLECTUAL PROPERTY RIGHTS 保持优势:保护您的知识产权 03 PROTECT YOURSELF AND YOUR BUSINESS: PRIORITISING IP PROTECTION IN PUBLIC LISTINGS & FUND RAISING 保护您自己和您的业务:在公共清单和筹款活动中优先考虑知识产权保护 04 REACHING SUCCESS: NEGOTIATING IP TERMS IN CONTRACTS 取得成功:谈判合同中的知识产权条款 INVESTMENT 投资 01 INVESTING IN WHAT THE GBA HAS TO OFFER, WHERE TO LOOK AND WHAT TO LOOK FOR 投资大湾区所提供的内容,寻找的地点和寻找的内容
02 ARTICULATING STRATEGIC VALUE OF YOUR ASSETS TO POTENTIAL INVESTORS AND PARTNERS 为潜在的投资者和合作伙伴提高资产的战略价值 03 NEW STRATEGIES IN LOWERING RISK AS AN INVESTOR 降低投资者风险的新策略 04 CHINA AS A KEY PLACE TO LOOK FOR INVESTORS AND MAKE INVESTMENTS 中国作为寻找投资者和进行投资的重要地点 05 INVESTING IN BIOTECH: EARLY STAGE INVESTMENTS AND TARGETING THE CORRECT MARKETS 投资生物科技:早期投资并瞄准正确的市场 06 INVESTMENT OPPORTUNITIES IN CHINA’S HEALTHCARE AND BIOTECH SECTOR AFTER COVID-19 中国医疗保健和生物科技领域在2019新型冠状病毒病以后的投资机会 LISTING AND IPO 上市及IPO 01 WHAT QUALIFIES AS AN 18A COMPANY? 十八A公司具备哪些资格? 02 EVALUATING YOUR COMPANY’S WORTH IN THE STOCK MARKET 在股票市场评估公司的价值 03 INCREASING YOUR CHANCES IN SUCCESSFULLY LISTING YOUR BIOTECH COMPANY IN HK 增加您在香港成功上市生物科技公司的机会 Cost effective approaches, accessing what the vast market the GBA has to offer 具有成本效益的方法,进入大湾区提供的广阔市场 04 UNDERSTANDING THE VARIOUS STAGES OF AN IPO: FROM EARLY TO PRE–IPO STAGE 了解首次公开募股的各个阶段:从早期到首次公开募股阶段 05 LISTING IN HONG KONG AS A PART OF YOUR GLOBAL STRATEGY: GROWING YOUR BUSINESS IN CHINA 在香港上市作为您全球战略的一部分:在中国发展业务 06 A GUIDE TO LISTING IN HONG KONG: FROM THE LISTING REQUIREMENTS FOR BIOTECH COMPANIES, BENEFITS AND THE TYPICAL TIMELINE OF AN IPO 香港上市指南:从生物科技公司的上市要求,收益和首次公开募股的典型时间表 07 BIOTECH IPOS: THE SILVER LINING AMIDST COVID-19 2019新型冠状病毒病中的一线希望 ...... AND MORE ...... 及更多 BIOHK2022 is the first international biotech convention to be held in Hong Kong and one of the first face-to-face meetings after COVID-19 for all to enjoy. BIOHK will present an exceptional international biotech kaleidoscope event to you. 香港国际生物科技展是首个在香港举行的国际生物科技展,也是2019新型冠状病毒病爆发之后第一批线下会议之一。 BIOHK将为您呈现一场国际生物科技万花筒盛会。 Copyright © 2020 Hong Kong Biotechnology Organisation. All rights reserved. Changed your mind? You can unsubscribe at any time.
版权所有 © 2020 香港生物科技协会 不再想要接收这些电子邮件? 按此退订 |